Apogee Therapeutics (APGE) Stock Overview
A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
APGE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Apogee Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.47 |
| 52 Week High | US$63.50 |
| 52 Week Low | US$26.20 |
| Beta | 1.44 |
| 1 Month Change | 42.27% |
| 3 Month Change | 34.95% |
| 1 Year Change | -7.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 147.15% |
Recent News & Updates
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
Jul 08Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
May 30
Recent updates
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
Jul 08Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans
May 30Apogee Therapeutics: Engineering Biologic Dominance
Apr 14We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Feb 13We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Nov 14Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Nov 10We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21Shareholder Returns
| APGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 31.6% | -0.1% | -2.7% |
| 1Y | -7.9% | -2.0% | 13.4% |
Return vs Industry: APGE underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: APGE underperformed the US Market which returned 13.4% over the past year.
Price Volatility
| APGE volatility | |
|---|---|
| APGE Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APGE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: APGE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 196 | Michael Henderson | www.apogeetherapeutics.com |
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases.
Apogee Therapeutics, Inc. Fundamentals Summary
| APGE fundamental statistics | |
|---|---|
| Market cap | US$3.07b |
| Earnings (TTM) | -US$237.67m |
| Revenue (TTM) | n/a |
Is APGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APGE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$237.67m |
| Earnings | -US$237.67m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APGE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/12 18:28 |
| End of Day Share Price | 2025/10/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apogee Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chen Yang | BofA Global Research |
| Timothy Anderson | BofA Global Research |
| Julian Harrison | BTIG |